logo-loader

Insights Widest with the analysis, Proactive gives perspectives that others don't.

research premium 1 research premium 1

research premium 1 research premium 1research premium 1research premium 1

on 16/12/19
Deep dive

Futura Medical looking ahead to completion of key phase III ED trial

Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also...

on 28/11/19
Deep dive

Synairgen excited for phase II trial results in 2020

The company has been developing a treatment for chronic lung disease in-house and has partnered...

on 28/11/19
Deep dive

AIM billionaire Clinigen is still growing at a rate of knots

Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire

on 28/11/19
Feature

AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot

Since the Frenchman took the helm in October 2012, the drug giant's share price has increased by...

on 27/11/19

Watch

Silence Therapeutics CEO talks recent RNAi deals and updates on critical...

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran. Solomon also updates on their lead candidate, SLN124, which is being developed to treat...

on 28/11/19

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.